FDA approves two Eylea biosimilars to treat macular degeneration, other eye conditions

Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy) are interchangeable biosimilars to Eylea (aflibercept). Aflibercept products, administered intravitreally, work by inhibiting VEGF which prevents abnormal blood vessel growth within the eye and slow down or reduce damage to the retina and help preserve vision. Both Yesafili and Opuviz are indicated for neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.